Dye-Driven Precision: Targeting Chemo Directly to Tumors
Lyle Small leads a biotech startup pursuing a bold new approach: dye-drug conjugates that carry chemotherapy directly to cancer...
Moe Alsumidaie
Why Correcting Trial Imaging Errors at Central Review Is Too Late—and Too Expensive
The patient drove two hours each way for the trial, which her oncologist and she believed was her best...
Northwell Christina Brennan on Future of Site-Sponsor Partnerships
At the Veeva R&D and Quality Summit in Boston, we interviewed Dr. Christina Brennan, Senior Vice President of Clinical...
FDA’s National Priority Voucher Program Is Just a Modular PMA Rebrand, With Risks
In June 2025, FDA announced its new Commissioner’s National Priority Voucher (CNPV) program, a headline-grabbing reform that promises to...
AI’s Transformative Role in Colorectal Cancer Screening
In the dynamic field of gastroenterology, AI is revolutionizing clinical practices, particularly in colorectal cancer screening. Dror Zur, CEO...
Redefining Imaging Workflows in Clinical Trials
At the Veeva R&D and Quality Summit in Boston, Moe Alsumidaie interviewed Jeff Sorenson, CEO of Yunu, and Steve...
What Research Sites Say They Need from Sponsors
At Veeva’s 2025 R&D & Quality Summit, site leaders described how brittle identity systems, sprawling vendor networks, and poorly...
How ICH E20 is Redefining Adaptive Clinical Trials
In the third month of a multi-arm trial for an aggressive brain cancer, the sponsor found itself facing a...
Pharma’s Next Opportunity: AI and Standardization
At Veeva R&D and Quality Summit in Boston, the pain points of managing complex processes and entering data manually...
ICH E6(R3) Raises the Bar on Imaging in Clinical Trials—Are You Ready?
When the FDA inspector arrived, no one expected imaging to be the issue. The scans had been read. The...